Yahoo · Nov 20, 2026
iShares U.S. Healthcare ETF (IYH) Sells $17.4 Million of Eli Lilly on Wednesday
The fund sold $105.9 million of stock and bought nothing, cutting all 99 of its positions.

NYSE · LLY
Healthcare · Drug Manufacturers - General
$1,351.12
Up+$2.88 (+0.21%)
Updated Nov 20, 2026, 5:43 PM
SID Score
6.8/10
Composite research score
Smart Money
44/100
Neutral
Price performance · LLY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
LLY closed at $1,351.12 after 21 trading sessions, up 3.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $1,369.38 | $1,382.00 | $1,341.46 | $1,351.12 | 3.2M |
| Nov 18, 2026 | $1,407.93 | $1,423.11 | $1,380.00 | $1,382.75 | 2.88M |
| Nov 17, 2026 | $1,415.995 | $1,432.2799 | $1,401.66 | $1,415.55 | 2.65M |
| Nov 16, 2026 | $1,453.75 | $1,475.25 | $1,427.66 | $1,431.67 | 3.21M |
| Nov 13, 2026 | $1,429.91 | $1,449.64 | $1,419.77 | $1,443.50 | 2.08M |
| Nov 12, 2026 | $1,446.55 | $1,460.00 | $1,427.28 | $1,427.28 | 2.41M |
| Nov 11, 2026 | $1,418.08 | $1,440.47 | $1,414.37 | $1,437.29 | 1.88M |
| Nov 10, 2026 | $1,408.49 | $1,438.88 | $1,400.00 | $1,432.29 | 3.02M |
| Nov 9, 2026 | $1,365.395 | $1,419.67 | $1,364.5829 | $1,411.95 | 4.03M |
| Nov 6, 2026 | $1,350.45 | $1,377.2771 | $1,333.22 | $1,354.00 | 3.81M |
| Nov 5, 2026 | $1,434.00 | $1,453.00 | $1,364.73 | $1,364.73 | 4.89M |
| Nov 4, 2026 | $1,440.00 | $1,445.96 | $1,401.59 | $1,417.99 | 3.64M |
| Nov 3, 2026 | $1,399.63 | $1,437.00 | $1,393.47 | $1,409.38 | 2.84M |
| Nov 2, 2026 | $1,393.15 | $1,421.99 | $1,382.02 | $1,410.99 | 3.74M |
| Oct 30, 2026 | $1,428.83 | $1,449.68 | $1,408.36 | $1,417.54 | 5.25M |
| Oct 29, 2026 | $1,332.73 | $1,408.38 | $1,330.00 | $1,373.70 | 4.37M |
| Oct 28, 2026 | $1,268.55 | $1,299.43 | $1,260.34 | $1,288.30 | 2.06M |
| Oct 27, 2026 | $1,273.50 | $1,297.92 | $1,272.0703 | $1,281.91 | 1.85M |
| Oct 26, 2026 | $1,286.39 | $1,296.90 | $1,273.7293 | $1,279.14 | 2.11M |
| Oct 23, 2026 | $1,304.15 | $1,307.9199 | $1,257.62 | $1,273.46 | 2.28M |
| Oct 22, 2026 | $1,281.76 | $1,321.21 | $1,275.10 | $1,306.69 | 2.66M |
The latest Smart Investors Daily articles mentioning LLY.
Company
Market Activity
Research & News
LLY research
Company profile and research snapshot.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 17, 2026 | RBC Capital | Outperform | — |
| Nov 16, 2026 | Barclays | Overweight | — |
| Nov 9, 2026 | Jefferies | Buy | — |
| Nov 2, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 30, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Nov 20, 2026
The fund sold $105.9 million of stock and bought nothing, cutting all 99 of its positions.
Yahoo · Nov 20, 2026
The $102.85 billion fund sold $136.0 million of stock and bought nothing, trimming 502 positions.
Yahoo · Nov 20, 2026
The fund sold $335.2 million of stock on Wednesday, Nov. 18, cutting all 60 of its positions and buying nothing.
Yahoo · Nov 20, 2026
ETFs sold $252.2 million of Eli Lilly (LLY) on Wednesday, with 39 buying and 20 selling.
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company shares traded at $1,382.54, reflecting a daily decline of 1.66% per SID market data. Despite the session pullback, the stock has demonstrated strong momentum across multiple timeframes, posting gains of 14.13% over the past month, 10.56% over three months, and 31.89% over the trailing twelve months. LLY currently trades well above both its 50-day moving average of $1,252.56 and its 200-day moving average of $1,111.25, confirming a sustained bullish technical trend. The 14-day relative strength index stands at 68.3, approaching but not yet breaching the traditional overbought threshold of 70. The company carries a market capitalization of approximately $906.5 billion, positioning it among the largest healthcare companies globally. Notably, LLY exhibits a beta of 0.369, according to SID market data, indicating significantly lower volatility relative to the broader market, a characteristic common among large-cap pharmaceutical stocks.
Eli Lilly trades at a price-to-earnings ratio of 49.16, a substantial premium to the broader healthcare sector, reflecting the market's pricing of robust future growth expectations tied to its GLP-1 receptor agonist portfolio, per SID market data. The PEG ratio stands at 1.47, suggesting the valuation remains elevated even when adjusting for projected earnings growth, though it falls within a range some frameworks consider reasonable for high-growth companies. The price-to-book ratio of 38.04 further underscores the significant premium investors are paying relative to the company's net asset value, according to SEC filings. Eli Lilly offers a modest dividend yield of approximately 0.59%, positioning it as a growth-oriented holding rather than an income play. Within the healthcare sector, these valuation multiples rank among the highest, consistent with LLY's status as a leading beneficiary of expanding demand for diabetes and obesity therapeutics driving top-line acceleration.
Eli Lilly's composite smart money score stands at 42 out of 100 with a neutral signal, reflecting a mixed picture across institutional and insider activity categories, per SID market data. Institutional positioning scores a perfect 25 out of 25, indicating maximum conviction among large asset managers and mutual funds holding significant stakes in the company, according to 13F institutional filings. In contrast, the insider trading component scores 4.1 out of 25 despite notable recent activity — 20 insider transactions were recorded over the past 90 days, with 15 purchases and 5 sales, according to SEC Form 4 filings. The buy-to-sell ratio of 3-to-1 suggests insiders have been net accumulating shares. Dark pool activity scores 9.3 out of 25, indicating moderate but unremarkable off-exchange institutional interest. Congressional trading activity registers at a low 3.2 out of 25. The divergence between strong institutional ownership signals and weaker insider and congressional scores produces the overall neutral composite reading.
Eli Lilly has delivered a consistent pattern of earnings beats across its three most recent reported quarters, according to company earnings reports. In the most recently reported period, the company posted earnings per share of $7.48 against a consensus estimate of $6.36, representing a positive surprise of $1.12. The prior quarter saw an even larger beat, with actual EPS of $8.38 versus the $6.01 estimate, a $2.37 upside surprise. The quarter before that produced EPS of $8.55 against a $6.85 estimate, a $1.70 beat. These three consecutive quarters of substantial outperformance indicate that analyst models have consistently underestimated the company's earnings power. Looking ahead, the upcoming quarter carries a consensus estimate of $8.84, per analyst estimates. The magnitude of recent surprises — averaging $1.73 per share across the last three quarters — suggests analysts may still be calibrating their models to the company's accelerating revenue trajectory.
Wall Street consensus on Eli Lilly remains unanimously bullish, with all five most recent analyst actions reiterating positive ratings, according to Wall Street analyst reports. On November 17, RBC Capital maintained its Outperform rating, following Barclays' reiteration of Overweight on November 16. Jefferies reaffirmed its Buy rating on November 9, while Cantor Fitzgerald maintained Overweight on November 2, per SID consensus data. RBC Capital had also previously reiterated Outperform on October 30, issuing two positive notes within an 18-day span. Notably, none of the recent actions reflect upgrades — all five represent reiterations of existing positive positions, indicating sustained rather than newly emerging bullish conviction. The absence of any Hold, Underweight, or Sell ratings among recent coverage actions underscores the degree of analyst alignment around the LLY growth thesis. The consistency across multiple major firms — including both bulge-bracket and independent research houses — reflects broad institutional confidence in the company's commercial and pipeline trajectory.


The latest Smart Investors Daily articles mentioning LLY.